IP Library Granted Patent US 7,026,346
Granted Patent B2
US 7,026,346 · App. 10/409,502 · Granted Apr 11, 2006

Compounds and methods for inducing apoptosis in proliferating cells

Assignee: The Ohio State University Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,026,346
App. No.
10/409,502
Granted
Apr 11, 2006
Kind
B2
Abstract

Compounds useful for inducing apoptosis in proliferative cells, particularly cancer cells, including but not limited to prostate cancer, leukemia, non-smalll cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, bladder cancer, lymphoma, and breast cancer. These compounds are particularly useful in the treatment of androgen-independent cancers, including hormone-refractory prostate cancer. Further provided are methods of treating cancer in a subject in need of such treatment using the compounds of the present invention. Further provided are methods for using the compounds of the present invention to treat, inhibit, or delay the onset of cancer in a subject. Further provided are methods of inducing apoptosis in rapidly proliferating cells, particularly, though not necessarily cancer cells, using the compounds of the present invention.

Claims (62)

1. A compound of formula I:

wherein

R 1 is carboxyamide;

R 2 is selected from the group consisting of alkyl and haloalkyl; and

Ar is an aryl radical selected from phenyl, biphenyl, naphthyl, anthryl, phenanthrenyl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, azido, C 1 –C 4 alkyl, C 1 –C 4 haloalkyl, C 1 –C 4 azidoalkyl, aryl, alkylaryl, haloaryl, haloalkylaryl, and combinations thereof;

or a pharmaceutically-acceptable salt thereof.

2. The compound of claim 1 wherein R 2 is selected from C 1 –C 4 alkyl and trifluoromethyl.

3. The compound of claim 2 wherein Ar is selected from the group consisting of 2-naphthyl, 4-biphenyl, 9-anthryl, 2-fluorenyl, 4-azidophenyl, 4-azidomethylphenyl, 4-(2-azidoethyl)phenyl, 4-(3-azidopropyl)phenyl, 4-(4-azidobutyl)phenyl, 4-(4-azidophenyl)phenyl, 4-(4-azidomethylphenyl)phenyl, 4-methylphenyl, 4-ethylphenyl, 4-propylphenyl, 4-butylphenyl, 4-(2-bromoethyl)phenyl, 4-(3-bromopropyl)phenyl, 4-(4-bromobutyl)phenyl, 4-(trifluoromethyl)phenyl, 4-(4-methylphenyl)phenyl, 4-(4-bromomethylphenyl)phenyl, 4-(4-butylphenyl)phenyl, 4-(4-tert-butylphenyl)phenyl, 2-chlorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,5-dichlorophenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 4-(4-chlorophenyl)phenyl, 4-(3,5-dichlorophenyl)phenyl, 4-(2,3-dichlorophenyl)phenyl, 4-(3,5-dimethylphenyl)phenyl, 4-(2,4,5-trichlorophenyl)phenyl, 4-(4-trifluoromethylphenyl)phenyl, 2-phenanthrenyl, 3-indolyl, 2-pyrrolyl, and 4-(benzyl)phenyl;

or a pharmaceutically-acceptable salt thereof.

4. A compound of formula II:

wherein

R 3 is selected from the group consisting of carboxyamide and sulfonamide;

R 4 is selected from alkyl and haloalkyl; and

Ar′ is selected from the group consisting of 4-azidophenyl, 4-(2-azidoethyl)phenyl, 4-(3-azidopropyl)phenyl, 4-(4-azidobutyl)phenyl, 4-(4-azidophenyl)phenyl, 4-(4-azidomethylphenyl)phenyl, 2,5-dimethylphenyl, 4-propylphenyl, 4-bromomethylphenyl, 4-(2-bromoethyl)phenyl, 4-(3-bromopropyl)phenyl, 4-(4-bromobutyl)phenyl, 4-(4-bromomethylphenyl)phenyl, 4-(4-tert-butylphenyl)phenyl, 9-anthryl, 4-(4-butylphenyl)phenyl, 4-(4-methylphenyl)phenyl, 4-(4-chlorophenyl)phenyl, 4-(3,5-dichlorophenyl)phenyl, 4-(2,3-dichlorophenyl)phenyl, 4-(3,5-dimethylphenyl)phenyl, 4-(2,4,5-trichlorophenyl)phenyl, 4-(4-trifluoromethylphenyl)phenyl, 2-phenanthrenyl, 3-indolyl, 2-pyrrolyl, 4-(benzyl)phenyl, and 2-fluorenyl;

or a pharmaceutically-acceptable salt thereof.

5. The compound of claim 4 , and the pharmaceutically acceptable salts thereof, selected from the group consisting of

4-[5-(4-azidophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(2-azidoethyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(3-azidopropyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(4-azidobutyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(4-butylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(4-methylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(4-azidophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(4-azidomethylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(4-chlorophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(3,5-dichlorophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(2,3-dichlorophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(3,5-dimethylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(2,4,5-trichlorophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-(4-trifluoromethylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(3-indolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(2-pyrrolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-benzylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;

4-[5-(4-azidophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(2-azidoethyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(3-azidopropyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-azidobutyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-azidophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-azidomethylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-propylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(2-bromoethyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-butylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-methylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(3-bromopropyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-bromobutyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-bromomethylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-tert-butylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(9-anthryl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(2-fluorenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-chlorophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(3,5-dichlorophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(2,3-dichlorophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(3,5-dimethylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(2,4,5-trichlorophenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(4-(4-trifluoromethylphenyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(3-indolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide;

4-[5-(2-pyrrolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide; and

4-[5-(4-benzylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenecarboxyamide.

6. The compound of claim 5 wherein the compound is 4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

Assignments (5)
CONFIRMATORY LICENSE Recorded Aug 22, 2020
From: THE OHIO STATE UNIVERSITY
To: NIH - DEITR; MRDC
Reel/Frame 053569/0356 →
CONFIRMATORY LICENSE Recorded Nov 18, 2015
From: THE OHIO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 037071/0760 →
CONFIRMATORY LICENSE Recorded Nov 18, 2015
From: THE OHIO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 037145/0322 →
CONFIRMATORY LICENSE Recorded Jul 30, 2009
From: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
To: US GOVERNMENT - SECRETARY FOR THE ARMY
Reel/Frame 023029/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2007
From: CHEN, CHING-SHIH; XUEQIN, SONG; LIN, HO-PI
To: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 020227/0275 →
Continuity (2)
Provisional Application 6037066400 · Apr 8, 2002
Related Publication 20030236294A1 · Dec 25, 2003